Miguel Martínez-Cava2026-10-01T07:00:04+02:00Fresenius completes acquisition of mAbxience, creating a stronger platform for future portfolio expansionMiguel Martínez-Cava2026-10-01T07:00:04+02:00October 1, 2026|
Miguel Martínez-Cava2026-09-18T07:16:55+02:00mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access WorldwideMiguel Martínez-Cava2026-09-18T07:16:55+02:00September 18, 2026|
Miguel Martínez-Cava2025-12-22T22:02:19+01:00mAbxience and Amneal Announce FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®Miguel Martínez-Cava2025-12-22T22:02:19+01:00December 22, 2025|